medigraphic.com
Colegio de Medicina Interna de México.

2025, Number 04

<< Back Next >>

Med Int Mex 2025; 41 (04)

Tegoprazan: Evidence and usefulness in clinical practice of the management of acidrelated diseases

Remes TJM, Vargas BJL

Language: Spanish
References: 49
Page: 234-249
PDF size: 433.84 Kb.


ABSTRACT

Background: Potassium-competitive acid blockers (P-CAB) represent an innovative class of drugs used to treat diseases related to gastric acid secretion, such as gastroesophageal reflux disease and peptic ulcers. Tegoprazan is a benzimidazole and is the first P-CAB available in Mexico.
Objective: To analyze the clinical evidence available of this molecule.
Methodology: A cross-search was conducted through the PubMed and Imbiomed portals (until February 2024) for the following terms (in Spanish and their respective translations and abbreviations in English): tegoprazan, ulcers, Helicobacter pylori, gastroesophageal reflux.
Results: Out of a total of 62 articles obtained in the search, information from 49 of them was included. According to the literature, tegoprazan overcomes the limitations of proton pump inhibitors (PPIs), thanks to its longer half-life and faster onset of action (from 15-30 minutes after ingestion). It has been shown to have solid evidence in terms of safety and effectiveness. Its clinical effectiveness has been demonstrated in inhithe treatment of erosive reflux disease and gastroduodenal ulcer, and it is an excellent option in optimizing the eradication of Helicobacter pylori infection.
Conclusions: Tegoprazan is an effective treatment for acid-related diseases and has pharmacological advantages compared to PPIs.


REFERENCES

  1. Sobrino-Cossío S, Teramoto-Matsubara O, Mateos-Pérez G,Abdo-Francis JM, et al. In search of the grail: A race for acidsuppression. Rev Gastroenterol Mex 2019; 84 (3): 344-56.https://doi.org.10.1016/j.rgmx.2019.04.002

  2. He J, Cao G, Yu J, Wang J, et al. Safety, tolerability andpharmacokinetics of single ascending and multiple oraldoses of tegoprazan in healthy chinese subjects. Clin DrugInvestig 2021; 41 (1): 89-97. https://doi.org.10.1007/s40261-020-00986-4

  3. Abdel-Aziz Y, Metz DC, Howden CW. Review article:potassium-competitive acid blockers for the treatment ofacid-related disorders. Aliment Pharmacol Ther 2021; 53(7): 794-809. https://doi.org.10.1111/apt.16295

  4. Chen D, Hagen SJ, Boyce M, Zhao CM. Neuroendocrinemechanism of gastric acid secretion: Historical perspectivesand recent developments in physiology and pharmacology.J Neuroendocrinol 2023; 35 (11): e13305. https://doi.org.10.1111/jne.13305

  5. Engevik AC, Kaji I, Goldenring JR. The physiology of thegastric parietal cell. Physiol Rev 2020; 100 (2): 573-602.https://doi.org.10.1152/physrev.00016.2019

  6. Ramsay PT, Carr A. Gastric acid and digestive physiology.Surg Clin North Am 2011; 91 (5): 977-82. https://doi.org.10.1016/j.suc.2011.06.010

  7. Sachs G, Shin JM, Howden CW. Review article: the clinicalpharmacology of proton pump inhibitors. Aliment PharmacolTher 2006; 23 Suppl 2: 2-8. https://doi.org.10.1111/j.1365-2036.2006.02943.x

  8. Sachs G, Shin JM, Pratha V, Hogan D. Synthesis or rupture:duration of acid inhibition by proton pump inhibitors. DrugsToday (Barc) 2003; 39 Suppl A: 11-4.

  9. Hunt RH, Scarpignato C. Potent acid suppression with PPIsand P-CABs: What’s new? Curr Treat Options Gastroenterol2018; 16 (4): 570-590. https://doi.org.10.1007/s11938-018-0206-y

  10. Chaudhry AS, Kochhar R, Kohli KK. Genetic polymorphismof CYP2C19 & therapeutic response to proton pump inhibitors.Indian J Med Res 2008; 127 (6): 521-30.

  11. Leowattana W, Leowattana T. Potassium-competitiveacid blockers and gastroesophageal reflux disease. WorldJ Gastroenterol 2022; 28 (28): 3608-3619. https://doi.org.10.3748/wjg.v28.i28.3608

  12. Oshima T, Miwa H. Potent potassium-competitive acidblockers: A new era for the treatment of acid-related diseases.J Neurogastroenterol Motil 2018; 24 (3): 334-344.https://doi.org.10.5056/jnm18029

  13. Scarpignato C, Hunt RH. The potential role of potassium-competitive acid blockers in the treatment ofgastroesophageal reflux disease. Curr Opin Gastroenterol2019; 35 (4): 344-355. https://doi.org.10.1097/MOG.0000000000000543

  14. Kim DK, Lee KH, Kim SJ, Kim SJ, et al . Effects of tegoprazan,a novel potassium-competitive acid blocker, on ratmodels of gastric acid-related disease. J Pharmacol ExpTher 2019; 369 (3): 318-327. https://doi.org.10.1124/jpet.118.254904

  15. Tanaka S, Morita M, Yamagishi T, Madapally HV, et al.Structural basis for binding of potassium-competitiveacid blockers to the gastric proton pump. J Med Chem2022; 65 (11): 7843-7853. https://doi.org.10.1021/acs.jmedchem.2c00338

  16. Jeong HC, Kim MG, Wei Z, Lee KR, et al. Integration of aphysiologically based pharmacokinetic and pharmacodynamicmodel for tegoprazan and its metabolite: applicationfor predicting food effect and intragastric pH alterations.Pharmaceutics 2022; 14 (6): 1298. https://doi.org.10.3390/pharmaceutics14061298

  17. Yoon DY, Lee S, Jang IJ, Kim M, et al. Prediction of drug–druginteraction potential of tegoprazan using physiologicallybased pharmacokinetic modeling and simulation. Pharmaceutics2021; 13 (9): 1489. https://doi.org.10.3390/pharmaceutics13091489

  18. Jeon JY, Kim SY, Moon SJ, Oh K, et al. Pharmacokineticinteractions between tegoprazan and metronidazole/tetracycline/bismuth and safety assessment in healthy Koreanmale subjects. Clin Ther 2021; 43 (4): 722-734. https://doi.org.10.1016/j.clinthera.2021.01.026

  19. Oh M, Lee H, Kim S, Kim B, et al. Evaluation of pharmacokineticdrug-drug interaction between tegoprazan and clarithromycinin healthy subjects. Transl Clin Pharmacol 2023;31 (2): 114-123. https://doi.org.10.12793/tcp.2023.31.e11

  20. Moon SJ, Shin N, Kang M, Kim B, Kim MG. Pharmacokineticinteractions between tegoprazan and naproxen, aceclofenac,and celecoxib in healthy Korean male subjects. ClinTher 2022; 44 (7): 930-944.e1. https://doi.org.10.1016/j.clinthera.2022.06.002

  21. Kim MG, Im YJ, Lee JH, Kim EY, et al. Comparison of hepatotoxicityof tegoprazan, a novel potassium-competitive acidblocker, with proton pump inhibitors using real-world data:A nationwide cohort study. Front Med (Lausanne) 2023;9: 1076356. https://doi.org.10.3389/fmed.2022.1076356

  22. Hong J Taek, Yoon H Jeon, et al. ep124 effects of tegoprazan,potassium competitive acid blocker, on thegastric emptying: a pilot study. Gastroenterology 2023;164 (6): S-1213-S-1214. https://doi.org/10.1016/S0016-5085(23)03807-6

  23. Bosques-Padilla FJ, Remes-Troche JM, González-Huezo MS,Pérez-Pérez G, et al . The fourth Mexican consensus on Helicobacterpylori. Rev Gastroenterol Mex (Engl Ed) 2018; 83(3): 325-341. https://doi.org.10.1016/j.rgmx.2018.05.003

  24. Malfertheiner P, Megraud F, Rokkas T, Gisbert JP, et al;European Helicobacter and Microbiota Study group. Managementof Helicobacter pylori infection: the Maastricht VI/Florence consensus report. Gut 2022: gutjnl-2022-327745.https://doi.org.10.1136/gutjnl-2022-327745

  25. Kim TH. Role of potassium-competitive acid blockers ineradication of Helicobacter pylori infection. Korean J InternMed 2023; 38 (4): 451-453. https://doi.org.10.3904/kjim.2023.250

  26. Shah A, Usman O, Zahra T, Chaudhari SS, Mulaka GSR,et al. Efficacy and safety of potassium-competitive acidblockers versus proton pump inhibitors as Helicobacterpylori eradication therapy: A meta-analysis of randomizedclinical trials. Cureus 2023; 15 (11): e48465. https://doi.org.10.7759/cureus.48465

  27. Jeon JY, Kim SY, Moon SJ, Oh K, et al. Pharmacokineticinteractions between tegoprazan and metronidazole/tetracycline/bismuth and safety assessment in healthy koreanmale subjects. Clin Ther 2021; 43 (4): 722-734. https://doi.org.10.1016/j.clinthera.2021.01.026

  28. Park CH, Park JH, Jung YS. Comparative efficacy of tegoprazanvs esomeprazole/sodium bicarbonate for the treatmentof Helicobacter pylori infection. Clin Transl Gastroenterol2023; 14 (11): e00632. https://doi.org.10.14309/ctg.0000000000000632

  29. Kwon YH, Jeon SW, Nam SY, Lee DW, et al. Ten-day tegoprazan-based concomitant therapy as a first-line treatment forHelicobacter pylori eradication. Korean J Intern Med 2023;38 (4): 493-503. https://doi.org.10.3904/kjim.2022.345.

  30. Kim JS, Ko W, Chung JW, Kim TH. Efficacy of tegoprazanbasedbismuth quadruple therapy compared with bismuthquadruple therapy for Helicobacter pylori infection: A randomized,double-blind, active-controlled study. Helicobacter2023; 28 (3): e12977. https://doi.org.10.1111/hel.12977

  31. Jung YS, Kim S, Kim HY, Noh SJ, et al. Efficacy and tolerabilityof 14-day tegoprazan- versus rabeprazole-based tripletherapy for eradication of Helicobacter pylori: A real-worldevidence study. Gut Liver 2023; 17 (5): 711-721. https://doi.org.10.5009/gnl220218

  32. Park CH, Song MJ, Jung BW, Park JH, Jung YS. Comparativeefficacy of 14-day tegoprazan-based triple vs. 10-daytegoprazan-based concomitant therapy for Helicobacterpylori eradication. J Pers Med 2022; 12 (11): 1918. https://doi.org.10.3390/jpm12111918

  33. Jung YS, Kim S, Kim HY, Noh SJ, et al. 7-day versus 14-daytegoprazan-based triple therapy to treat Helicobacterpylori infection: Real-world evidence. J GastroenterolHepatol 2022; 37 (10): 1911-1918. https://doi.org.10.1111/jgh.15939

  34. Choi YJ, Lee YC, Kim JM, Kim JI, et al. Triple therapy-basedon tegoprazan, a new potassium-competitive acid blocker,for first-line treatment of Helicobacter pylori infection: Arandomized, double-blind, phase III, clinical trial. Gut Liver2022; 16 (4): 535-546. https://doi.org.10.5009/gnl220055

  35. Kim JY, Lee SY, Kim H, Kim JH, Sung IK, Park HS. Efficacy ofseven-day potassium-competitive acid blocker-based firstlineHelicobacter pylori eradication therapy administeredwith bismuth. Yonsei Med J 2021; 62 (8): 708-716. https://doi.org.10.3349/ymj.2021.62.8.708

  36. Huerta-Iga F, Bielsa-Fernández MV, Remes-Troche JM,Valdovinos-Díaz MA, Tamayo-de la Cuesta JL; en representacióndel Grupo para el estudio de la ERGE 2015.Diagnosis and treatment of gastroesophageal refluxdisease: recommendations of the Asociación Mexicanade Gastroenterología. Rev Gastroenterol Mex 2016; 81(4): 208-222. https://doi.org.10.1016/j.rgmx.2016.04.003

  37. Devault KR, Johanson JF, Johnson DA, Liu S, Sostek MB.Maintenance of healed erosive esophagitis: a randomizedsix-month comparison of esomeprazole twenty milligramswith lansoprazole fifteen milligrams. Clin GastroenterolHepatol 2006; 4 (7): 852-9. https://doi.org.10.1016/j.cgh.2006.03.006

  38. Shin CM, Choi SC, Cho JW, Kim SY, et al. Comparison of tegoprazanand lansoprazole in patients with erosive esophagitis:a multicenter, randomized, double-blind, activecomparatorphase 4 trial. Gastroenterology 2023; 164 (6):S-204. https://doi.org/10.1016/S0016-5085(23)01449-X

  39. Lee KJ, Son BK, Kim GH, Jung H, et al. Randomised phase3 trial: tegoprazan, a novel potassium‐competitive acidblocker, vs. esomeprazole in patients with erosive oesophagitis.Aliment Pharmacol Ther 2019; 49 (7): 864-872.https://doi.org/10.1111/apt.15185

  40. Cho YK, Kim JH, Kim HS, Kim TO, et al. Randomised clinicaltrial: comparison of tegoprazan and lansoprazole asmaintenance therapy for healed mild erosive oesophagitis.Aliment Pharmacol Ther 2023; 57 (1): 72-80. https://doi.org/10.1111/apt.17255

  41. Kim JS, Seo SI, Kang SH, Lee SK, et al. Effects of tegoprazanversus esomeprazole on nighttime heartburn and sleepquality in gastroesophageal reflux disease: a multicenterdouble-blind randomized controlled trial. J NeurogastroenterolMotil 2023; 29 (1): 58-64. https://doi.org/10.5056/jnm22104

  42. Han S, Choi HY, Kim YH, Choi S, et al. Comparison of pharmacodynamicsbetween tegoprazan and dexlansoprazoleregarding nocturnal acid breakthrough: A randomizedcrossover study. Gut Liver 2023; 17 (1): 92-99. https://doi.org/10.5009/gnl220050

  43. Yang E, Kim S, Kim B, Kim B, et al. Night‐time gastric acidsuppression by tegoprazan compared to vonoprazan oresomeprazole. Br J Clin Pharmacol 2022; 88 (7): 3288-3296.https://doi.org/10.1111/bcp.15268

  44. Kim SH, Cho KB, Chun HJ, Lee SW, et al . Randomised clinicaltrial: comparison of tegoprazan and placebo in non-erosivereflux disease. Aliment Pharmacol Ther 2021; 54 (4): 402-411. https://doi.org/10.1111/apt.16477

  45. Laine L, Jensen DM. Management of patients with ulcerbleeding. Am J Gastroenterol 2012; 107: 345-360. https://doi.org/10.1038/ajg.2011.480

  46. Lanas A, Chan FKL. Peptic ulcer disease. Lancet 2017;390 (10094): 613-624. https://doi.org/10.1016/S0140-6736(16)32404-7

  47. Dong Y, Xu H, Zhang Z, Zhou Z, Zhang Q. Comparative efficiencyand safety of potassium competitive acid blockersversus Lansoprazole in peptic ulcer: a systematic reviewand meta-analysis. Front Pharmacol 2024; 14: 1304552.https://doi.org/10.3389/fphar.2023.1304552

  48. Cho YK, Choi MG, Choi SC, Lee KM, et al. Randomised clinicaltrial: tegoprazan, a novel potassium-competitive acidblocker, or lansoprazole in the treatment of gastric ulcer.Aliment Pharmacol Ther 2020; 52 (5): 789-797. https://doi.org/10.1111/apt.15865

  49. Kim BW, Park JJ, Moon HS, Lee WS, et al . The effect of tegoprazanon the treatment of endoscopic resection-inducedartificial ulcers: a multicenter, randomized, active-controlledstudy. Gut Liver 2024. https://doi.org/10.5009/gnl230242




2020     |     www.medigraphic.com